CAR-T cell therapy is chimeric antigen receptor T cell immunotherapy, which is a new type of precision-targeted therapy for the treatment of tumors.
This article is the "Profitability" part of the enterprise value series, and a total of 36 cell immunotherapy companies are selected as research samples, and the return on net assets, gross profit margin, net profit margin, etc. are used as evaluation indicators.
Data is based on history and does not represent future trends; It is for static analysis only and does not constitute investment advice.
Top 10 Cellular Immunotherapy Profitability Companies:
10th Dongcheng Pharmaceutical
Profitability: Return on equity 4.92%, gross profit margin 42.92%, net profit margin 8.09%
Main products: API-related products are the main source of revenue, accounting for 51.21% of revenue and gross profit margin of 26.10%
Company Highlights: Yuyan Biotech, a company owned by Dongcheng Pharmaceutical, focuses on the research and development, production and preparation of cell immunotherapy technology, production preparation and technical services, as well as tumor-specific antigen screening and amniotic stem cell research and development.
9th Boji Pharmaceutical
Profitability: Return on equity 4.12%, gross profit margin 38.16%, net profit margin 8.41%
Main products: clinical research services are the main source of revenue, accounting for 74.57% of revenue, and gross profit margin is 32.68%
Company Highlights: Boji Pharma currently has several clinical research projects for CAR-T cell therapy.
8th Guanhao Creatures
Profitability: Return on equity -10.87%, gross margin 76.83%, net profit margin -23.75%
Main products: Biological dura (spinal) membrane patch is the main source of revenue, accounting for 21.69% of revenue, and gross profit margin is 91.18%
Company Highlights: Guanhao Bio has cooperated with a number of clinical medical centers to complete the incubation research of multiple CAR-T cell projects in the field of tumor biotherapy.
7th Energizing Health
Profitability: Return on equity 9.32%, gross profit margin 34.97%, net profit margin 7.64%
Main products: Terminal business and services are the main source of revenue, accounting for 62.36% of revenue, and gross profit margin of 42.69%
Company Highlights: OriCell Biosciences, a subsidiary of Canature Health Strategic Investment, has brought the innovative CAR-T therapy, TIL cell therapy and antibody drugs that it has developed to clinical research and translational applications.
6th Hengrui Pharmaceutical
Profitability: Return on equity 11.95%, gross profit margin 84.57%, net profit margin 18.00%
Main products: anti-tumor is the main source of revenue, accounting for 53.54% of revenue, gross profit margin of 91.82%
Company Highlights: Hengrui Pharmaceutical's camrelizumab for injection can bind to the human PD-1 receptor and block the PD-1/PD-L1 pathway, restore the body's anti-tumor immunity, thereby forming the basis of cancer immunotherapy.
5th WuXi AppTec
Profitability: Return on equity 17.89%, gross margin 38.25%, net profit margin 23.03%
Main products: chemical business is the main source of revenue, accounting for 72.31% of revenue, gross profit margin of 44.52%
Company Highlights: WuXi AppTec has completed the construction of an adeno-associated virus (AAV) suspension and adherent dual process platform and an integrated closed manufacturing platform for CAR-T cell therapy to support global customers.
No. 4 Yao Kee Technology
Profitability: Return on equity 19.29%, gross profit margin 39.00%, net profit margin 12.62%
Main products: digital marketing is the main source of income, accounting for 44.38% of revenue, gross profit margin of 5.45%
Company Highlights: The Shanghai Cell Therapy Engineering Technology Research Center, which is owned by Yao Kee Technology, is engaged in the development of technologies in the fields of cell therapy technology, biotechnology, and laboratory equipment technology.
No. 3 Zuoli Pharmaceutical
Profitability: Return on equity 12.99%, gross profit margin 70.14%, net profit margin 16.37%
Main products: Wuling series is the main source of income, accounting for 63.21% of revenue, gross profit margin of 86.50%
Company Highlights: CARsgen Biopharma, in which Zuoli Pharmaceutical Co., Ltd. is a shareholder, has a total of three CAR-T cell products, which are CAR-T cell therapy drugs for the treatment of liver cancer, hematologic tumors, and multiple myeloma.
No. 2 Zhifei Biology
Profitability: Return on equity 47.74%, gross profit margin 36.53%, net profit margin 22.75%
Main products: Agency products are the main source of income, accounting for 98.05% of revenue, and gross profit margin of 25.68%
Company Highlights: Zhirui Investment, an investment company established by Zhifei Biotech, mainly invests in drugs for tumors (such as monoclonal antibodies, CAR-T, etc.), metabolic diseases, cardiovascular diseases and other major diseases.
1st Anke Biotech
Profitability: Return on equity 18.73%, gross profit margin 78.94%, net profit margin 23.66%
Main products: Genetic engineering drugs are the main source of revenue, accounting for 70.91% of revenue, and gross profit margin is 86.08%
Company Highlights: Anke Biotech Co., Ltd., a shareholding company, focuses on the field of specific cell immunotherapy.
The top 10 companies in terms of cell immunotherapy profitability, return on net assets, gross profit margin and net profit margin in the past three years:
